Real-world clinical study on the efficacy and safety of Honghua Ruyi Wan in treating primary dysmenorrhea
ZHANG Ke-jun
NIU Bing-qian
LI Qian
JIN Lu-kuo
LUO Xiao-mei
BIAN Wen-hui
CHEN Hui-juan
JIAO Rui-qin
HOU Jing-jing
GUO Feng-he
CUI Jun
FANG Jin-fen
LIU Cheng-zang
CUI Meng-jiao
SONG Wen-wen
GONG Cheng-feng
LIU Dong-yong
TIAN Gui-fang
SHEN Wei-ping
XU Lang-ping
LI Su-fang
CHEN Mei-xia
GAO Su-yun
YANG Ai-ling
HAO Zhi-feng
YANG Li
Abstract：Objective:To evaluate the efficacy and safety of Honghua Ruyi Wan(HHRYW)in patients with primary dysmenorrhea(PD).Methods:A multi-center,large-sample,self-controlled before-after clinical trial was designed.A total of 671 PD patients were enrolled to receive HHRYW treatment.The Visual Analogue Scale(VAS)score and COX menstrual symptom scale(CMSS)score were compared before and after the treatment.Results:In PD patients treated with HHRYW alone,both VAS and CMSS scores were significantly reduced compared to the baseline(P<0.0001).Within and between different treatment duration groups,there was statistically significant differences in VAS score improvement(P<0.0001).The severity and duration of PD-related symptoms were also significantly reduced post-treatment(P<0.0001).The improvement of VAS score in patients with cold coagulation and blood stasis type and Qi stagnation and blood stasis type was better than that in other syndrome types(P<0.000 1).Conclusion:HHRYW significantly alleviates pain severity(in patients with VAS scores≥4,indicating moderate-to-severe PD)and improves dysmenorrhea-related symptoms,especially for patients with cold coagulation and blood stasis type and Qi stagnation and blood stasis type.Its clinical application is worth promoting.
Keywords：primary dysmenorrheaHonghua Ruyi Wanvisual analogue scaleCOX menstrual symptom scaleclinical trial
Publication Date：2025-11-15
Online Publishing Date：2026-08-14(First online date of this platform, not the publication date of the document)
Pages：6( 2300-2305 )